Who owns Nurix Therapeutics, Inc. (NRIX)? Elite investor 13F holders
2 tracked elite investors reported holding Nurix Therapeutics, Inc as of 2026-06-30, including Rubric Capital, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Rubric Capital | Nurix Therapeutics Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 175345894.00 USD | 7227778.000000 | Shares | add | Original filing |
| D.E. Shaw | Nurix Therapeutics Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 4477207.00 USD | 184551.000000 | Shares | reduce | Original filing |
| Renaissance Technologies LLC | Nurix Therapeutics Inc | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.